Previous Article | Next Article ![]()
Infection and Immunity, March 2001, p. 1322-1328, Vol. 69, No. 3
Department of Microbiology, Technical
University of Denmark, DK-2800 Lyngby, Denmark
Received 17 August 2000/Returned for modification 18 October
2000/Accepted 23 November 2000
Type 1 fimbriae are surface-located adhesion organelles of
Escherichia coli that are directly associated with
virulence of the urinary tract. They mediate
D-mannose-sensitive binding to different host surfaces by
way of the minor fimbrial component FimH. Naturally occurring variants
of FimH that bind strongly to terminally exposed monomannose residues
have been associated with a pathogenicity-adaptive phenotype that
enhances E. coli colonization of extraintestinal locations
such as the urinary tract. The FimH adhesin also promotes biofilm
formation in a mannose-inhibitable manner on abiotic surfaces under
static growth conditions. In this study, we used random mutagenesis
combined with a novel selection-enrichment technique to
specifically identify mutations in the FimH adhesin that confer on
E. coli the ability to form biofilms under hydrodynamic flow (HDF) conditions. We identified three FimH variants from our
mutant library that could mediate an HDF biofilm formation phenotype to various degrees. This phenotype was induced by the cumulative effect of multiple changes throughout the receptor-binding region of the protein. Two of the HDF biofilm-forming FimH variants were insensitive to mannose inhibition and represent novel phenotypes not previously identified in naturally occurring isolates.
Characterization of our enriched clones revealed some similarities to
amino acid alterations that occur in urinary tract infection (UTI)
strains. Subsequent screening of a selection of UTI FimH variants
demonstrated that they too could promote biofilm formation on abiotic
surfaces under HDF conditions. Interestingly, the same correlation
was not observed for commensal FimH variants. FimH is a
multifaceted protein prone to rapid microevolution. In
addition to its previously documented roles in adherence and invasion,
we have now demonstrated its function in biofilm formation on abiotic
surfaces subjected to HDF conditions. The study indicates that UTI FimH
variants possess adaptations that enhance biofilm formation and
suggests a novel role for FimH in UTIs associated with medical implants such as catheters.
Most bacteria living in aquatic
environments form sessile communities referred to as biofilms. Biofilms
are compact microbial communities consisting of organisms adherent to
each other and/or a target surface. They can consist of either
monocultures or multispecies communities and show
extraordinary resistance to mechanisms that efficiently remove
free-swimming bacterial relatives (8, 9). Bacterial
biofilms can establish on virtually any solid surface of inorganic or
organic nature spanning a wide spectrum of environments (8). Bacterial adherence is instrumental for the
successful establishment of sessile bacterial communities on mammalian
tissue surfaces, notably on surfaces subjected to hydrodynamic flow
(HDF) shear forces such as the urinary tract. The best-characterized group of bacterial adhesins is constituted by fimbriae
(13). Type 1, or mannose-sensitive, fimbriae are found on
the majority of Escherichia coli strains and are widespread
among other members of the family Enterobacteriaceae
(16). Interaction between type 1 fimbriae and receptor
structures has in a number of studies been shown to play a key role in
the colonization of various host tissues by E. coli
(2, 40). Also, in certain strain backgrounds type 1 fimbriae can be regarded as virulence factors. Indeed, we and others
have previously shown that the expression of type 1 fimbriae in
E. coli is linked to urinary tract colonization and
pathogenesis (7, 25, 36). In animal models, immunization with the type 1 fimbrial adhesin was shown to prevent urogenital mucosal infection by E. coli (20, 21).
A typical type 1-fimbriated bacterium has 200 to 500 peritrichously
arranged fimbriae on its surface. A type 1 fimbria is a 7-nm-wide,
approximately 1-µm-long, rod-shaped structure consisting of four
different components that are added to the base of the growing
organelle (22). The bulk of the structure consists of about 1,000 copies of the major subunit protein, FimA, polymerized into
a right-handed helical structure, but small quantities of the minor
components, FimF, FimG, and FimH are also present (14, 19). It has been shown that the receptor-recognizing element of
type 1 fimbriae is the 30-kDa FimH protein (18). FimH is located at the organelle tip in a short fibrillum and perhaps additionally intercalated along the fimbrial shaft (12,
18). The FimF and FimG components seem to be required for
integration of the FimH adhesin into the fimbriae (12,
14). The components of the fimbrial organelle are encoded by the
chromosomally located fim gene cluster (15). In
addition to the structural components, this 9.5-kb DNA segment also
encodes the fimbrial biosynthesis machinery as well as regulatory
elements (Fig. 1).
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.3.1322-1328.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Biofilm Formation in a Hydrodynamic
Environment by Novel FimH Variants and Ramifications for
Virulence
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

View larger version (10K):
[in a new window]
FIG. 1.
Schematic representation of plasmids used to display
FimH variants. Plasmid pPKL115 contains the entire fim gene
cluster with a translational stop linker inserted into the
fimH gene (triangle). Plasmid pMAS1 is the fimH
expression vector upon which all functional variants constructed in
this study are based. The segment flanked by the KpnI and
HincII sites was submitted to mutagenesis. Only relevant
nonvector regions are shown.
By virtue of the FimH adhesin, type 1 fimbriae mediate adhesion to a variety of mannosylated glycoproteins. Additionally, a number of studies have revealed that FimH adhesins from certain clinical isolates confer binding to protein targets such as fibronectin and collagen. This specificity change was found to be due to minor variations in the amino acid sequence of FimH (27, 38). Also, the affinity of FimH variants toward mannose targets can vary due to changes in the primary structure. In about 80% of fecal E. coli isolates, the FimH adhesin is capable of binding only to trimannose receptors. In contrast, the FimH adhesins from approximately 70% of urinary tract isolates carry minor mutations (compared to the fecal isolates) that enhance their ability to recognize monomannose receptors (37). The mutant alleles confer a significantly higher tropism for the uroepithelium (36).
The FimH adhesin has been shown to be instrumental in biofilm formation by E. coli K-12 under static growth conditions (28). Type 1 fimbriae were found to be critical for the initial interaction of E. coli cells with abiotic surfaces. Furthermore, this attachment could be inhibited by D-mannosides, indicating a specific role for FimH in such interactions. The FimH adhesin is a two-domain protein, with the NH2-terminal half conferring its lectin-binding characteristics (5, 17, 21, 33, 39). In a previous study we described the construction of a FimH mutant library by PCR-induced random mutagenesis within this region of the fimH gene (34). Specific mutations that altered the ability of FimH to bind to monomannose, oligomannose, and protein targets were identified. In this work we have screened the same FimH mutant library for variants with an ability to confer biofilm formation under HDF conditions, i.e., a scenario that arguably mimics many natural environments better than static conditions.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Bacterial strains, plasmids, and growth conditions.
The
strains and plasmids used in this study are listed in Table
1. E. coli K-12 strain HB101
(F' lacIq kan) (3) was
used as an intermediate host during plasmid construction work. All
subsequent phenotypic analyses were performed in the E. coli
fim strain S1918 (4). The FimH expression
vector pMAS1 contains the fimH gene from E. coli
K-12 strain PC31 (15) under transcriptional control of the
lac promoter. In addition, the plasmid contains unique
KpnI and HincII recognition sequences within the
fimH gene that flank the region encoding the proposed FimH
receptor-binding domain (Fig. 1). Cells were grown in Luria-Bertani (LB) broth (30) supplemented with the appropriate
antibiotics.
|
DNA techniques. Plasmid DNA was isolated using a QIAprep spin plasmid kit (Qiagen). Restriction endonucleases were used as specified by the manufacturer (New England Biolabs or Pharmacia). The nucleotide sequences were determined on both DNA strands by the dideoxynucleotide chain termination method (31). Oligonucleotide primers were purchased from Gibco BRL.
Construction of the fimH mutant library.
Construction of the fimH mutant library has been described
previously (34). Briefly, the 650-bp
KpnI-HincII fragment of the fimH gene
from pMAS1 was mutagenized by nucleotide misincorporation during
suboptimal PCR conditions. Four reactions were performed, with three of
the four nucleotides at a concentration of 50 mM and the other at 5 mM.
Each reaction mixture also contained 7 mM MgCl2 to increase
the stability of noncomplementary base pairs and 0.5 mM
MnCl2 to reduce the template specificity of the polymerase. The error-prone PCR procedure was performed for 35 cycles with two
primers that flank the KpnI and HindII sites
of the fimH gene. The amplification products were combined,
digested with KpnI and HincII, purified after
agarose gel electrophoresis, and religated into similarly cut plasmid
pMAS1 to construct a library of altered fimH genes. To
permit expression of the corresponding FimH variants as functional
constituents of type 1 fimbriae, the ligation mix was transformed into
E. coli strain S1918 (
fim) containing an auxiliary plasmid, pPKL115, which encodes the entire fim
gene cluster except fimH. The transformation mixture was
made up to 10 ml, grown to approximately 10 times the initial library
diversity, and stored as aliquots at
80°C in 25% (vol/vol)
glycerol. Analysis of 300 random transformants revealed that the
mutagenesis procedure was highly successful, with approximately 60% of
transformants displaying an altered yeast agglutination phenotype.
Construction of defined fimH mutations. Specific amino acid substitutions from the mutant fimH genes were introduced into the wild-type fimH sequence by overlapping PCR. The following primers were used: ms1 (5'-GTGATAAGCTTCACCATACCTACAGC), ms2 (5'-GCTCGAATTCCAGCATTAGCAATGTCC), 137 (5'-ATAATCGAGAACGGATAAGC), and 138 (5'-GCTTATCCGTTCTCGAATTAT). Each construct was sequenced to ensure fidelity of the PCR. Plasmids containing these chimeric fimH genes were introduced into S1918(pPKL115) and tested for yeast agglutination and biofilm formation.
Biofilm screening assay.
An aliquot of the fimH
mutant library was grown overnight in LB and diluted to approximately
108 cells ml
1 in phosphate-buffered saline
(PBS), and 100-µl aliquots were placed in 10 wells of a polystyrene
microtiter plate. The plate was incubated at 37°C for 1 h with
shaking and washed with 10 times with PBS; any remaining bound cells
were then resuspended in 100 µl of LB. Following growth overnight at
37°C with shaking the cells were diluted to approximately
108 cells ml
1, and the procedure was carried
out three more times. After the last incubation, the cultures were
streaked for single colonies.
Agglutination of yeast cells. The capacity of bacteria to express a D-mannose-binding phenotype was assayed by their ability to agglutinate yeast (Saccharomyces cerevisiae) cells on glass slides. Aliquots of washed bacterial suspensions at OD550 = 0.5 and 5% yeast cells were mixed, and the time agglutination occurred was measured. Furthermore, clones which did not cause any agglutination under these conditions were also tested at OD550 = 20 and/or low temperature but still did not react.
| |
RESULTS |
|---|
|
|
|---|
Identification of FimH variants capable of HDF biofilm
formation.
In E. coli K-12, type 1 fimbriation was
shown to be critical for biofilm formation on abiotic surfaces under
static growth conditions; this property could be abolished by addition
of methyl-
-D-mannopyranoside, indicative of FimH
involvement (Fig. 2A)
(28). However, under HDF conditions, the wild-type (wt)
FimH adhesin was unable to confer biofilm formation (Fig. 2B). We
hypothesized that variants of the FimH adhesin that would induce
biofilm formation under HDF conditions could be selected for. To
identify such variants we screened our FimH mutant library, which
consists of a pool of fimH genes with PCR-introduced random
mutations within the receptor-binding region of the FimH adhesin. More
specifically, the mutagenesis was targeted to the region encompassing
amino acids 8 to 225 of the mature FimH protein (34). An
aliquot of the FimH mutant library (approximately 108 cells
ml
1) was incubated in a polystyrene microtiter plate and
subjected to the selection-enrichment procedure described in Materials
and Methods.
|
Characterization of biofilm forming mutants.
The nucleotide
sequences of the fimH genes from the 30 HDF biofilm-forming
clones were determined. The sequences revealed that there were indeed
only three different clone types; the three plasmids were referred to
as pMAS58, pMAS60, and pMAS64. Plasmid pMAS58 was found in 24 of the 30 clones, plasmid pMAS60 was found in 5 of the clones, and plasmid pMAS64
was present in 1 clone. All of the amino acid changes were located
within the first 155 amino acids of the mature FimH protein (Fig.
3). Two of the FimH variants (pMAS58 and
pMAS60) contained multiple amino acid changes, while the FimH of
plasmid pMAS64 had only two amino acid changes. The abilities of
the clones to form a biofilm under HDF conditions differed (Fig. 2).
The FimH variant encoded on pMAS58 conferred the highest level of
biofilm formation, being about 2.5- and 6.5-fold better than pMAS60 and
pMAS64, respectively. This feature was reflected in the enrichment
frequency (80% of all isolated biofilm-forming clones).
|
Inhibition by soluble inhibitors.
Under natural conditions
bacterial adhesion to eucaryotic cells is a function of the ability of
the adhesin to interact with the cognate receptor on the cell
surface but also depends on the sensitivity of the adhesin to
soluble inhibitory compounds that often bathe the cellular target.
Since the mutations in all three clones fall within the
D-mannose receptor recognition domain of FimH, we
speculated that the sensitivity to soluble inhibitors might be
affected. Therefore, we determined the sensitivity of the FimH variants
to biofilm formation under HDF conditions in the presence of
methyl-
-D-mannopyranoside. Interestingly, the biofilm-forming abilities of strains harboring pMAS58 and pMAS60 were
only partially (35 and 10%, respectively) reduced under these conditions (Fig. 2). In previously described experiments
(28), FimH-mediated biofilm formation under static
growth conditions was abolished by D-mannose. Thus, the
pMAS58 and pMAS60 FimH variants possess novel phenotypes that
have not been previously identified. In contrast to these results, the
weaker biofilm-forming FimH variant encoded by pMAS64 could not form a
biofilm in the presence of methyl-
-D-mannopyranoside.
Detailed analysis of the amino acid changes in FimH. In an attempt to define the amino acid changes in FimH responsible for biofilm formation under HDF conditions, we used overlapping PCR to split the mutations (Fig. 3). The fimH gene in the predominant plasmid, pMAS58, contained nine amino acid-altering mutations. The split derivative plasmids pPKL236 and pPKL237 both turned out to be weaker HDF biofilm formers than the parent. This suggests that the inherent biofilm formation phenotype of the pMAS58 FimH variant is the cumulative result of several mutations within different regions of the receptor-binding domain. In contrast, the HDF biofilm-forming phenotype of plasmids pMAS60 (six changes) and pMAS64 (two changes) could be at least partly attributed to a mutation, G73E, found in both FimH variants. Apart from the presence of this mutation in both clones, a significant biofilm-forming potential was present in one of the split clones of pMAS60, i.e., pPKL239, harboring this mutation, whereas the other split clone, pPKL238, exhibited no HDF biofilm formation (Fig. 2). This led us to focus on the G73E change. Indeed, when the G73E mutation was uniquely introduced into the wt fimH, resulting in plasmid pTBK31 (Fig. 3), an HDF biofilm-forming phenotype was observed (Fig. 2). Taken together, the data demonstrate that a single amino acid substitution can enhance the binding repertoire of the FimH adhesin and permit adhesion to and biofilm formation on an abiotic surface under HDF conditions.
Agglutination phenotypes of FimH variants. The classical way to monitor type 1 fimbria-mediated adhesion to eucaryotic cells is agglutination of erythrocytes or yeast cells. Yeast cell agglutination is the most conserved binding property among natural E. coli isolates and therefore was used to evaluate the receptor binding exhibited by the biofilm-forming FimH variants. The pMAS58 FimH conferred a weak agglutination phenotype. Splitting of the mutations in this variant resulted in an increased ability to agglutinate yeast cells in both progeny clones (Fig. 3). In contrast, the pMAS60 FimH did not confer an ability to agglutinate yeast cells. Furthermore, analysis of the split clones revealed that some combination of the S114R, N136Y, Q143L, and V155G mutations was responsible for abolishing the mannose-binding ability of FimH. In this respect it is important to note that mutagenesis of position 136 was previously shown to abolish agglutination (33). The pMAS64 FimH also exhibited a reduced capacity to agglutinate yeast cells.
Biofilm formation induced by wt fimH alleles.
We
identified the G73E mutation of the pMAS60 FimH variant as a functional
alteration involved in biofilm formation under HDF conditions.
Interestingly, the same mutation has also been identified in the
pathogenicity-adapted FimH variant of a wt urinary tract isolate
(38). The mutation in this variant imparts a higher affinity for monomannose targets and thus provides an adaptive advantage for the bacterial colonization of the urinary tract (34, 36). We speculated that there might exist a
correlation between UTI FimH pathoadaptive phenotypes and HDF biofilm
formation potential. To test this, we examined a selection of clones
expressing previously characterized wt fimH alleles from
urinary tract isolates (37) for the ability to form
biofilms on abiotic surfaces. Indeed, all three of the strains tested
turned out to be very good HDF biofilm formers. Furthermore, unlike our
enriched clones, this biofilm formation phenotype could be inhibited by
mannose (Fig. 4). Two of these strains
(KB53 and KB96) also formed striking biofilms on glass surfaces under
HDF conditions (Fig. 5).
|
|
| |
DISCUSSION |
|---|
|
|
|---|
In natural aquatic environments surfaces are often exposed to HDF conditions. The urinary tract is such an example, and bacteria infecting the urinary tract are faced with brutal HDF shear forces. An obvious way for bacteria to counter this problem is to express efficient adhesions, enabling them to attach and eventually form sessile communities or biofilms. More than 50% of all microbial infections have now been associated with the formation of biofilms (9). In the urinary tract, biofilm formation is associated with chronic cystitis and infections related to medical implants such as catheters (24). The majority (80%) of urinary tract infections in humans are caused by E. coli. UTIs are a huge burden on our health care system; it is estimated that between 50 and 80% of women will experience at least one UTI infection at some time (11).
Uropathogenic E. coli express a number of different adhesive organelles including type 1, P, S, and F1C fimbriae. It is now well established that type 1 fimbriae are required for E. coli virulence of the urinary tract and that the FimH adhesin is instrumental in this regard (7, 25, 36). More recent data indicate that FimH can directly trigger host cell signaling cascades that lead to bacterial internalization (23). Type 1 fimbriae have also been described as key factors in biofilm establishment on abiotic surfaces (29). More specifically, the FimH adhesin was shown to be required for adherence to abiotic surfaces under static growth conditions. In this study, we used a novel random mutagenesis approach followed by a selection-enrichment procedure to specifically identify FimH variants capable of mediating biofilm formation on abiotic surfaces. Furthermore, to more realistically mimic real-life scenarios, our selection procedure was performed under HDF conditions.
We have previously demonstrated that the PCR mutagenesis approach used to construct our FimH mutant library was highly successful for the introduction of a limited number of random structural alterations in the FimH primary sequence. Nucleotide sequences were distributed randomly along the target sector, and the observed amino acid changes were diverse in nature (34). Therefore, it is intriguing that although the targeted region encompassed codons 8 to 225, no changes resulting in amino acid alterations were identified in the fimH alleles of the three clones enriched for HDF biofilm formation downstream of codon 155. For the sake of completeness, it should be noted that the fimH allele of plasmid pMAS60 contained two nucleotide changes downstream of codon 155 that did not alter the amino acid sequence. Thus, it appears that FimH-mediated biofilm formation as defined by our selection procedure is specifically linked to alterations in the N-terminal receptor-binding domain of the protein.
We identified three FimH variants that could mediate biofilm formation on abiotic surfaces subjected to HDF conditions. Two of these HDF biofilm library clones (pMAS58 and pMAS60) were partly immune to mannose inhibition. The strongest biofilm former identified in our selections was that encoded by the most predominantly enriched plasmid, pMAS58. From our split clones it is clear that some combination of the W103R, S113G, and V118A alterations is critical to impart this phenotype. In the case of plasmid pMAS60, biofilm formation was also associated with multiple amino acid changes. Our data indicates that the G73E mutation is required in combination with other changes to produce this phenotype. This mutation was also present in an independently isolated clone (pMAS64), providing additional evidence that it has a functional impact on the HDF biofilm formation phenotype. Furthermore, when the G73E change was introduced separately into the parental K-12 FimH background (i.e., plasmid pTBK31), enhanced biofilm formation was observed. When we compared the mutations in our enriched clones with those already documented in UTI FimH variants, some striking similarities were noted. First, the G73E mutation has been identified as the functional change in a naturally occurring FimH variant (38). In the case of the FimH encoded by the predominant plasmid pMAS58, the functional changes associated with biofilm formation partially overlap with a deletion of four amino acids (117 to 120) identified in another naturally occurring UTI FimH variant (38). These similarities between our own in vitro-selected clones and naturally occurring pathogenicity-adapted isolates prompted us to investigate biofilm formation mediated by naturally occurring FimH variants.
We examined three UTI FimH variants for their role in biofilm formation on abiotic surfaces subjected to HDF conditions. These variants have been well characterized with regard to their mannose-binding properties, and all contain minor amino acid changes in their amino-terminal domains that result in altered receptor specificity (35, 38). Furthermore, all three recombinant strains carrying the wt fimH alleles are similar with regard to level of fimbriation and relative levels of FimH incorporation, and importantly they are identical to the respective parental clinical isolates with regard to FimH adhesive phenotypes (37). We observed that these structural changes also impart an ability to form HDF biofilms on abiotic surfaces. It is intriguing to speculate on this correlation and the implications for pathogenesis. The ability to form biofilms is clearly a well-defined virulence trait among bacteria infecting the urinary tract (9). Thus, in addition to adhesion to mannose-containing substrates, FimH may be critical for the formation of biofilms in a hydrodynamic environment such as the urinary tract. Furthermore, the data implicate FimH as a potential mediator of biofilm formation on abiotic medical devices such as catheters.
FimH variants from E. coli strains of human fecal origin differ in receptor specificity from those from UTI isolates. Indeed, FimH variants from commensal isolates primarily recognize oligomannose-like receptors, while those from UTI isolates preferentially bind monomannose-like receptors and provide an adaptive advantage for bacterial colonization of the urinary tract (36). We examined HDF biofilm formation mediated by FimH variants from two commensal strains isolated from human fecal flora (E. coli K-12 strain PC31 and the wt strain F-18). Contrary to the FimH variants of UTI origin, the FimH variants from both of the commensal strains did not promote significant biofilm formation on abiotic surfaces under HDF conditions. Taken together, these findings suggest that the UTI FimH variants may have a greater capacity for HDF biofilm formation. At this stage one can only speculate on the role such FimH variants might play in establishing biofilms in the urinary tract, especially in catheterized patients. Although there might not be a complete correlation between HDF biofilm-forming FimH variants and pathogenicity, it may be that the biofilm assay described here could be used as a crude, yet simple and inexpensive means for differentiation of clinical isolates to indicate potential UTI pathogens.
Complicated UTIs and bacterial biofilms on the surface of catheters are often refractory to treatment with antibiotics. Our current knowledge suggests a multifunctional role for FimH in virulence traits that encompass adhesion, biofilm formation, and invasion. Our proposed role for FimH in biofilm formation on surfaces subjected to HDF conditions may lead to a better understanding in the design of treatment regimens to prevent UTIs. We have shown that the pathogenicity-adaptive phenotype that specifies altered affinity for different FimH alleles toward monomannose and trimannose can now be extended to include adherence to abiotic surfaces under HDF conditions. This novel phenotype has not previously been observed in naturally occurring FimH variants. Natural UTI FimH variants are probably functional compromises selected for their abilities to target and bind to mannose receptors and to form HDF biofilm. It is possible that the specific FimH isotypes enriched in our assays represent adhesive phenotypes selected against in the urinary tract. A highly intriguing aspect of this work is the observation that UTI FimH alleles possess greater biofilm formation potential than their commensal FimH counterparts.
| |
ACKNOWLEDGMENTS |
|---|
We thank Birthe Jul Jørgensen for expert technical assistance and David Hasty (University of Tennessee) and Evgeni Sokurenko (University of Washington) for providing strains.
This work was supported by the Danish Medical Research Council (grant 9802358).
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Microbiology, Bldg. 301, Technical University of Denmark, DK-2800 Lyngby, Denmark. Phone: 45 45 25 25 06. Fax: 45 45 93 28 09. E-mail: impk{at}pop.dtu.dk.
Editor: A. D. O'Brien
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Bachmann, B. J. 1996. Derivations and genotypes of some mutant derivatives of Escherichia coli K-12, p. 2460-2488. In F. C. Neidhardt, R. Curtis III, J. L. Ingraham, E. C. C. Lin, K. B. Low, B. Magasanik, W. S. Reznikoff, M. Riley, M. Schaechter, and H. E. Umbarger (ed.), Escherichia coli and Salmonella: cellular and molecular biology, 2nd ed. ASM Press, Washington, D.C. |
| 2. | Bloch, C. A., B. A. D. Stocker, and P. E. Orndorff. 1992. A key role for type 1 pili in enterobacterial communicability. Mol. Microbiol. 6:697-701[CrossRef][Medline]. |
| 3. | Boyer, H. W., and D. Roulland-Dussoix. 1969. A complementary analysis of the restriction and modification of DNA in Escherichia coli. J. Mol. Biol. 41:459-472[CrossRef][Medline]. |
| 4. |
Brown, S.
1992.
Engineering iron oxide-adhesion mutants of the Escherichia coli phage lambda receptor.
Proc. Natl. Acad. Sci. USA
89:8651-8655 |
| 5. |
Choudhury, D.,
A. Thompson,
V. Stojanoff,
S. Langermann,
J. Pinker,
S. J. Hultgren, and S. D. Knight.
1999.
X-ray structure of the FimC-FimH chaperone-adhesin complex from uropathogenic Escherichia coli.
Science
285:1061-1066 |
| 6. |
Cohen, P. S.,
J. C. Arruda,
T. J. Williams, and D. C. Laux.
1985.
Adhesion of a human fecal Escherichia coli strain to mouse colonic mucus.
Infect. Immun.
48:139-145 |
| 7. |
Connell, H.,
W. Agace,
P. Klemm,
M. Schembri,
S. Måarild, and C. Svanborg.
1996.
Type 1 fimbrial expression enhances Escherichia coli virulence for the urinary tract.
Proc. Natl. Acad. Sci. USA
93:9827-9832 |
| 8. | Costerson, J. W., Z. Lewandowski, D. E. Caldwell, D. R. Korber, and H. M. Lappin-Scott. 1995. Microbial biofilms. Annu. Rev. Microbiol. 49:711-745[CrossRef][Medline]. |
| 9. |
Costerson, J. W.,
P. S. Stewart, and E. P. Greenberg.
1999.
Bacterial biofilms: a common cause of persistent infections.
Science
284:1318-1322 |
| 10. | Genevaux, P., S. Muller, and P. Bauda. 1996. A rapid screening procedure to identify mini-Tn10 insertion mutants of Escherichia coli K-12 with altered adhesion properties. FEMS Microbiol. Lett. 142:27-30[CrossRef][Medline]. |
| 11. | Gupta, K., and W. E. Stamm. 1999. Pathogenesis and management of recurrent urinary tract infections in women. World J. Urol. 17:415-420[CrossRef][Medline]. |
| 12. |
Jones, C. H.,
J. S. Pinkner,
R. Roth,
J. Heuser,
A. V. Nicholes,
S. N. Abraham, and S. J. Hultgren.
1995.
FimH adhesin of type 1 pili is assembled into a fibrillar tip structure in the Enterobacteriaceae.
Proc. Natl. Acad. Sci. USA
92:2081-2085 |
| 13. | Klemm, P. 1994. Fimbriae: adhesion, genetics, biogenesis and vaccines. CRC Press, Inc., Boca Raton, Fla. |
| 14. | Klemm, P., and G. Christiansen. 1987. Three fim genes required for the regulation of length and mediation of adhesion of Escherichia coli type 1 fimbriae. Mol. Gen. Genet. 208:439-445[CrossRef][Medline]. |
| 15. | Klemm, P., B. J. Jørgensen, I. van Die, H. de Ree, and H. Bergmans. 1985. The fim genes responsible for synthesis of type 1 fimbriae in Escherichia coli. Mol. Gen. Genet. 199:410-414[CrossRef][Medline]. |
| 16. | Klemm, P., and K. A. Krogfelt. 1994. Type 1 fimbriae of Escherichia coli, p. 9-26. In P. Klemm (ed.), Fimbriae, adhesion, genetics, biogenesis and vaccines. CRC Press, Inc., Boca Raton, Fla. |
| 17. |
Knudsen, T. B., and P. Klemm.
1998.
Probing the receptor recognition site of the FimH adhesin by fimbriae-displayed FimH-FocH hybrids.
Microbiology
144:1919-1929 |
| 18. |
Krogfelt, K. A.,
H. Bergmans, and P. Klemm.
1990.
Direct evidence that the FimH protein is the mannose-specific adhesin of Escherichia coli type 1 fimbriae.
Infect. Immun.
58:1995-1998 |
| 19. | Krogfelt, K. A., and P. Klemm. 1988. Investigation of minor components of Escherichia coli type 1 fimbriae: protein chemical and immunological aspects. Microb. Pathog. 4:231-238[CrossRef][Medline]. |
| 20. | Langermann, S., R. Mollby, J. E. Burlein, S. R. Palaszynski, C. G. Auguste, A. DeFusco, R. Strouse, M. A. Schenerman, S. J. Hultgren, J. S. Pinkner, J. Winberg, L. Guldevall, M. Soderhall, K. Ishikawa, S. Normark, and S. Koenig. 2000. Vaccination with FimH adhesin protects cynomolgus monkeys from colonization and infection by uropathogenic Escherichia coli. J. Infect. Dis. 181:774-778[CrossRef][Medline]. |
| 21. |
Langermann, S.,
S. Palaszynsky,
M. Barnhart,
G. Auguste,
J. S. Pinkner,
J. Burlein,
P. Barren,
S. Koenig,
S. Leath,
C. H. Jones, and S. J. Hultgren.
1997.
Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination.
Science
276:607-611 |
| 22. |
Lowe, M. A.,
S. C. Holt, and B. I. Eisenstein.
1987.
Immunoelectron microscopic analysis of elongation of type 1 fimbriae in Escherichia coli.
J. Bacteriol.
169:157-163 |
| 23. | Martinez, J. J., M. A. Mulvey, J. D. Schilling, J. S. Pinkner, and S. J. Hultgren. 2000. Type 1 pilus-mediated bacterial invasion of bladder epithelial cells. EMBO 19:2803-2812[CrossRef][Medline]. |
| 24. | Morris, N. S., D. J. Stickler, and R. J. C. McLean. 1999. The development of bacterial biofilms on indwelling urethral catheters. World J. Urol. 17:345-350[CrossRef][Medline]. |
| 25. |
Mulvey, M. A.,
Y. S. Lopez-Boado,
C. L. Wilson,
R. Roth,
W. C. Parks,
J. Heuser, and S. J. Hultgren.
1998.
Induction and evasion of host defenses by type 1-piliated uropathogenic Escherichia coli.
Science
282:1494-1497 |
| 26. |
Pallesen, L.,
L. K. Poulsen,
G. Christiansen, and P. Klemm.
1995.
Chimeric FimH adhesin of type 1 fimbriae: a bacterial display system for heterologous sequences.
Microbiology
141:2839-2848 |
| 27. | Pouttu, R., T. Puustinen, R. Virkola, J. Hacker, P. Klemm, and T. K. Korhonen. 1999. Amino acid residue Ala-62 in the FimH fimbrial adhesin is critical for the adhesiveness meningitis-associated Escherichia coli to collagens. Mol. Microbiol. 31:1747-1757[CrossRef][Medline]. |
| 28. | Pratt, L. A., and R. Kolter. 1998. Genetic analysis of Escherichia coli biofilm formation: roles of flagella, motility, chemotaxis and type I pili. Mol. Microbiol. 30:285-293[CrossRef][Medline]. |
| 29. | Pratt, L. A., and R. Kolter. 1999. Genetic analyses of bacterial biofilm formation. Curr. Opin. Microbiol. 2:598-603[CrossRef][Medline]. |
| 30. | Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. |
| 31. |
Sanger, F.,
S. Nicklen, and A. R. Coulson.
1977.
DNA sequencing with chain-terminating inhibitors.
Proc. Natl. Acad. Sci. USA
74:5463-5467 |
| 32. |
Schembri, M. A., and P. Klemm.
1998.
Heterobinary adhesins based on the Escherichia coli FimH fimbrial protein.
Appl. Environ. Microbiol.
64:1628-1633 |
| 33. | Schembri, M. A., L. Pallesen, H. Connell, D. L. Hasty, and P. Klemm. 1996. Linker insertion analysis of the FimH adhesin of type 1 fimbriae in an Escherichia coli fimH-null background. FEMS Microbiol. Lett. 137:257-263[CrossRef][Medline]. |
| 34. |
Schembri, M. A.,
E. V. Sokurenko, and P. Klemm.
2000.
Functional flexibility of the FimH adhesin: insights from a random mutant library.
Infect. Immun.
68:2638-2646 |
| 35. |
Sokurenko, E. V.,
V. Chesnokova,
R. J. Doyle, and D. L. Hasty.
1997.
Diversity of Escherichia coli type 1 fimbrial lectin.
J. Biol. Chem.
272:17880-17886 |
| 36. |
Sokurenko, E. V.,
V. Chesnokova,
D. E. Dykhuizen,
I. Ofek,
X.-R. Wu,
K. A. Krogfelt,
C. Struve,
M. A. Schembri, and D. L. Hasty.
1998.
Pathogenic adaptation of Escherichia coli by natural variation of the FimH adhesin.
Proc. Natl. Acad. Sci. USA
95:8922-8926 |
| 37. |
Sokurenko, E. V.,
H. S. Courtney,
J. Maslow,
A. Sitonen, and D. L. Hasty.
1995.
Quantitative differences in adhesiveness of type 1 fimbriated Escherichia coli due to structural differences in fimH genes.
J. Bacteriol.
177:3680-3686 |
| 38. |
Sokurenko, E. V.,
H. S. Courtney,
D. E. Ohman,
P. Klemm, and D. L. Hasty.
1994.
FimH family of type 1 fimbrial adhesins: functional heterogeneity due to minor sequence variations among fimH genes.
J. Bacteriol.
176:748-755 |
| 39. | Thankavel, K., B. Madison, T. Ikeda, R. Malavia, A. H. Shah, P. M. Arumugam, and S. N. Abraham. 1997. Localization of a domain in the FimH adhesin of Escherichia coli type 1 fimbriae capable of receptor recognition and use of a domain-specific antibody to confer protection against experimental urinary tract infection. J. Clin. Investig. 100:1123-1136[Medline]. |
| 40. | Yamamoto, T., K. Fujita, and T. Yokota. 1990. Adherence characteristics to human intestinal mucosa of Escherichia coli isolated from patients with diarrhea or urinary tract infections. J. Infect. Dis. 162:896-908[Medline]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»